Heptares Therapeutics and AstraZeneca to Research GPCR Drug Targets
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 6 (Table of Contents)
Published: 10 Jun-2011
DOI: 10.3833/pdr.v2011.i6.1483 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
UK biotech Heptares Therapeutics has entered into 4-year research collaboration with AstraZeneca to leverage its GPCR (G-protein coupled receptor) expertise and proprietary StaR® technology with the aim of building a pipeline of GPCR-targeted drugs for CNS/pain, cardiovascular/metabolic and inflammatory disorders based on projects from AstraZeneca’s small and large molecule portfolio, including from its MedImmune biologics unit...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS